Herren Wu is Senior Vice President and Head of Antibody Discovery and Protein Engineering (ADPE), R&D at AstraZeneca.lol外围

Herren founded the Department of Antibody Discovery and Protein Engineering in January 2002. During his tenure, Herren has successfully integrated ADPE platforms across R&D. Under his leadership, ADPE has developed many proprietary cutting-edge technology platforms, including half-life extension technology (YTE), bi-specifics/multi-specifics, protein scaffolds, antibody-drug conjugates, Blood-Brain-Barrier technology, peptide therapeutics, phenotypic screening and most recently mass-spec proteomics and non-natural amino acid technology.

In 2006, Herren received the Senior Technology Fellow Emerald Honors award. He is also an inventor on 43 granted patents and 50 patent applications related to antibody/protein therapeutics and technologies. This is in addition to 更多 than 60 manuscript publications.

Herren received his bachelor’s degree in Chemistry from the National Taiwan University and his doctorate in Molecular and Cellular Biology from the University of Massachusetts, Amherst. He completed his postdoctoral training at The Scripps Research Institute in La Jolla, California.

Through our work extending the half-life of antibodies, we overcame the challenges and put the antibody to the test in human clinical trials and it worked. It's like a Eureka! moment. Not many people can have that type of experience.

Herren Wu Senior Vice President and Head of Antibody Discovery and Protein Engineering (ADPE), R&D
S10外围

lol外围

lol外围

lols10外围登录

lol外围

lol外围

lols10下注

lol外围

lol外围

lols10外围押注

LATEST PROJECT

LOL下注网站

LEADERSHIP

LOL下注网站

STRATEGY

LOL下注网站

NON-MAB TECHNOLOGIES

LOL下注网站

LOL下注网站

Oligospecific antibodies for simultaneous targetinglol外围

Dimasi N, Gao C, Fleming R et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. Mol. Biol. 2009. 393(3):672-92

IgG1 enhanced binding to FcRn lol外围

Dall'Acqua WF, Kiener PA, Wu H. J. Properties of human IgG1s engineered for enhanced binding to FcRn. Biol. Chem. 2006: 281(33):23514-24

Building zinc fingerslol外围

Wu H, Yang WP, Barbas CF 3rd. Building zinc fingers by selection: towards a therapeutic application. Proc. Natl. Acad. Sci. USA.1995; 92(2):344-8.

LOL下注网站

and help us deliver life-changing medicines 

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.